MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Immune checkpoint inhibition for the treatment of mesothelioma.

Expert Opinion on Biological Therapy 2019 May 2 [Link] Nowak AK, McDonnell A, Cook A Abstract Combination chemotherapy is currently standard care for advanced mesothelioma. Checkpoint blockade is a promising new treatment. Areas covered: This review covers clinical use and biomarkers of checkpoint blockade. Medline search used keywords ‘mesothelioma’ combined with ‘checkpoint blockade’ OR ‘PD-L1’ […]

Comments Off on Immune checkpoint inhibition for the treatment of mesothelioma.

AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression.

Molecular Oncology 2019 April 29 [Link] Qin Y, Sekine I, Hanazono M, Morinaga T, Fan M, Takiguchi Y, Tada Y, Shingyoji M, Yamaguchi N, Tagawa M Abstract Pemetrexed (PEM) inhibits DNA and RNA synthesis and is currently one of the first-line agents for mesothelioma. PEM suppresses the activities of several enzymes involved in purine and […]

Comments Off on AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression.

Management of Malignant Pleural Mesothelioma in the Elderly Population.

Annals of Surgical Oncology 2019 April 22 [Link] Verma V, Wegner RE, Ludmir EB, Hasan S, Colonias A, Grover S, Friedberg JS, Simone CB 2nd Abstract BACKGROUND: The median age at diagnosis for malignant pleural mesothelioma (MPM) is approximately 72 years. Elderly patients pose unique management challenges because of the increased risk of therapy-related toxicities and […]

Comments Off on Management of Malignant Pleural Mesothelioma in the Elderly Population.

Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.

Clinical Lung Cancer 2019 March 26 [Link] Verma V, Wegner RE, Brooks ED, Miccio JA, Kann BH, Finley GG, Raj MS, Grover S, Mohindra P, Simone CB Abstract BACKGROUND: Management options for unresected malignant pleural mesothelioma (MPM) are largely limited to palliative chemotherapy and best supportive care. This study sought to delineate subgroups most likely […]

Comments Off on Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.

Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

La Radiologia Medica 2019 April 8 [Link] Trovo M, Franceschini D, Furlan C, Pietrobon F, Vagge S, Farina E, Revelant A, Visani L, Maragna V, Parisi G, Scotti V Abstract PURPOSE: To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, […]

Comments Off on Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies-Experience from Indian Centers.

Indian Journal of Surgical Oncology 2019 February [Link] Patel MD, Damodaran D, Rangole A, Shaikh S, Shah K, Bagwade R, Bhatt A Abstract Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in addition to radical surgery for primary and secondary pleural malignancies to improve local control, prolong survival, and improve the quality of life. This study was […]

Comments Off on Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies-Experience from Indian Centers.

Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.

Oncology Letters 2019 March [Link] Kai Y, Tsutani Y, Tsubokawa N, Ito M, Mimura T, Miyata Y, Okada M Abstract The present study analyzed surgical results in patients with malignant pleural mesothelioma (MPM) who underwent extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). Data for 44 patients who achieved macroscopic complete resection following neoadjuvant chemotherapy followed by […]

Comments Off on Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.

Radiology and Oncology 2019 March 3 [Link] Senk B, Goricar K, Kovac V, Dolzan V, Franko Abstract Background Malignant mesothelioma (MM) is an asbestos related aggressive tumor with poor prognosis. The aim of this study was to investigate if aquaporin 1 (AQP1) genetic polymorphisms influence the risk of MM and the response to cisplatin based […]

Comments Off on Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

Current Treatment Options in Oncology 2019 February 21 [Link] Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D’Argento E Abstract Unresectable or relapsed malignant pleural mesothelioma (MPM) has dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog allows a modest survival benefit, […]

Comments Off on Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Genome Medicine 2019 February 18 [Link] Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen […]

Comments Off on BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.